Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #182003 on Biotech Values
DewDiligence
01/06/15 10:44 AM
#185527 RE: DewDiligence #182003
Gilead Sciences, Inc. and Phenex Pharmaceuticals AG, a privately-held biotechnology company, today announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Under the terms of the agreement, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.